CPC Class C12Q

The present invention includes compositions and methods for eliminating or reducing microbial contamination in lymph nodes that enter the food supply from livestock comprising: identifying an animal in need of eliminating or reducing microbial contamination in non-gut associated lymph nodes that enter the food supply, and providing the animal with an effective amount of a lactic acid bacteria or probiotic bacterial sufficient to reduce or eliminate the microbial contamination in non-gut associated lymph nodes.

Nucleic acid origami devices are provided that are non-immunogenic and/or resistant to nucleases, which may be activated by one or more external cues, such as ligands, glucose concentration or electromagnetic fields; or used for attenuation or prevention of internalization of cell-surface receptors or prolongation of shelf-life of active agents. Further provided are methods for treating diabetes and methods for preparing the devices.

The invention relates to a covering device (10), in particular a lid, for covering reaction vessels (50), in particular PCR plates, microtiter plates, and the like, comprising: a substantially flat main body (14) having an inside (34) and an outside (12), at least one planar sealing element (36) arranged on the main body (14) and connected to the main body, wherein the at least one sealing element (36) is arranged on the inside (34) of the main body (14), an edge segment (16), which runs along the periphery of the main body and extends from the outside (12) in the direction of the inside (34) and beyond the inside, and at least one spring element (22, 24) arranged on the main body (14) or on the sealing element (36), which at least one spring element is designed in such a way that the at least one spring element supports the covering device (10) on a surface (54) of a reaction vessel (50) to be covered facing the covering device (10) in the relaxed state of the at least one spring element and that an intermediate space (56) is formed between the sealing element (36) and the surface (54) of the reaction vessel (50).

The invention provides an antibody or antigen binding fragment thereof capable of binding to the antigen binding pocket of the AP33 antibody, wherein said antibody or antigen binding fragment thereof comprises VL CDR1 (L1), VL CDR2 (L2), and VL CDR3 (L3) consisting of the amino acid sequences of SEQ ID NO:1, SEQ ID NO:2 and SEQ ID NO:23 respectively, and comprises VH CDR1 (H1), VH CDR2 (H2), and VH CDR3 (H3) consisting of the amino acid sequences of SEQ ID NO:24, SEQ ID NO:25, and SEQ ID NO:26 respectively. The invention also provides compositions, methods, nucleic acids and uses.

The present disclosure is directed to systems and methods for sampling and/or controlling the productivity of a bioreactor.

The invention provides an isolated, purified population of human cells comprising CD8+ T cells with reduced Cbl-b activity. The invention provides uses of such cells in methods for inducing or enhancing an anti-tumor immune response in a subject. These methods comprise: (a) providing a cell population, from a subject or from another source, which comprises CD8+ T cells, (b) reducing Cbl-b activity in the CD8+ T-cells, (c) administering the cells of step (b) to the subject. The invention provides methods for making CD8+ T cells that do not require stimulation through a co-receptor in order for the cell to become activated or proliferated in response to contact via its T cell receptor. Such methods are based upon reducing function of Cbl-b. The invention also provides methods for identifying agents which affect Cbl-b expression or activity.

In an illustrative embodiment, automated multi-module cell editing instruments are provided to automate multiple edits into nucleic acid sequences inside one or more cells.

The present disclosure provides a DNA-targeting RNA that comprises a targeting sequence and, together with a modifying polypeptide, provides for site-specific modification of a target DNA and/or a polypeptide associated with the target DNA. The present disclosure further provides site-specific modifying polypeptides. The present disclosure further provides methods of site-specific modification of a target DNA and/or a polypeptide associated with the target DNA The present disclosure provides methods of modulating transcription of a target nucleic acid in a target cell, generally involving contacting the target nucleic acid with an enzymatically inactive Cas9 polypeptide and a DNA-targeting RNA. Kits and compositions for carrying out the methods are also provided. The present disclosure provides genetically modified cells that produce Cas9; and Cas9 transgenic non-human multicellular organisms.

The method includes binding living cells to magnetic particles, adding them to a sensor array, uniformly distributing over the sensor array, magnetically fixing the magnetic particles having the bound cells over the sensor array, and adding substances to maintain and/or improve the cell vitality to the sensory array, and/or adding substances to worsen the cell vitality to the sensor array. The assembly includes a sensor array composed of sensors, which are designed to be in direct fluidic contact with a fluid, and a device for generating a magnetic field over the sensor array. A layer that comprises magnetic particles and living cells is formed on the sensor array.